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The indication and eﬀectiveness of low-dose
erythromycin therapy in pediatric patients
with bronchial asthma*
Low-dose erythromycin (EM) has been adminis-
teredtopatientswithchronicrespiratorydiseases,
such as diﬀuse panbronchiolitis and chronic
pansinusitis to suppress the neutrophilic inﬂam-
mationprocessofinterleukin(IL)8(1).Regarding
the bronchial asthma, low-dose EM therapy has
not been indicated for patients with bronchial
asthma because the essential mechanism of bron-
chial asthma is considered as an eosinophilic
inﬂammation; if anything, the co-administration
of EM and theophylline has beenavoided because
EM inhibits the theophylline metabolism (2).
Recently, several reports (3, 4) showed the eﬀec-
tiveness of low dose macrolide antibiotics in some
patients with bronchial asthma, however, the
indication of this therapy and the inﬂuence to
theophylline metabolism have not been examined
especially in pediatric patients.
In this study, to elucidate the eﬀectiveness and
the indication of low dose EM therapy, serum
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To elucidate the mechanisms of intractable pediatric bronchial asthma
and the indication of low-dose erythromycin (EM) therapy, the serum
chemokine levels of and the angiogenic factor were evaluated in 55
pediatric patients with bronchial asthma; 7.4 ± 3.5 yr old, who had
been treated with inhaled steroid, leukotriene receptor antagonist, the-
ophylline and others for more than a year. Both the levels of interleukin
(IL) 8 (p = 0.036) and vascular endothelial growth factor (VEGF)
(p = 0.005) were higher in patients with severe type than those of
patients with the milder type, while other chemokine levels such as
serum eotaxin and MCP1 did not show the correlation with the severity
of bronchial asthma. Induction of therapy with low-dose EM induced
improvement of the clinical symptoms in patients with severe type and
decrease of their serum chemokine levels: IL8; from 736 ± 88 to
75 ± 85 pg/ml (p < 0.0005), and VEGF; from 352.0 ± 160.5 to
132.2 ± 59.9 pg/ml (p = 0.021) within the next 6 months. Moreover,
low-dose EM resulted in a decreased daily peak-trough ﬂuctuation rate
of the serum theophylline concentration; (Cmax ) Cmin)/Cmin, from
1.3 ± 0.5 to 0.5 ± 0.3, which led to the maintenance of eﬀective serum
levels. These results indicated that IL8 and VEGF aﬀect the severity of
standard therapies resistance intractable bronchial asthma. Through the
suppression of these chemokines and maintenance of eﬀective theoph-
ylline levels, low-dose EM therapy improves the symptoms of bronchial
asthma.
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489chemokine characterization and the theophylline
metabolism in pediatric patients with bronchial
asthma were evaluated.
Patients
Fifty-ﬁve pediatric patients with bronchial
asthma; 7.4 ± 3.5 yr old and 10 age-matched
non-allergic non-febrile disease controls were
included in this study after obtaining the
informed consent from both the children and
their parents. The diagnosis and severity of
bronchial asthma were evaluated using the global
initiative for asthma (GINA) guidelines (6); a
positive speciﬁc IgE to such environmental aller-
gens as house dust mites, Japanese cedar and
others, a peripheral blood eosinophilia and an
obstructive respiratory function pattern. These
patients had been administered inhaled steroids
(ﬂuticasone; 200–400 lg/day), leukotriene recep-
tor antagonists, theophylline and others for more
than a year. Through those standard therapies,
most patients with bronchial asthma improved
their clinical symptoms, however, only four
patients repeatedly developed moderate-severe
asthma attack. Regarding the clinical severity of
asthma, four patients showed severe-intractable
type, 23 patients showed moderate-type and 28
patients showed mild-type.
Methods
Patient blood samples were collected during a
stable state without any infections or fever at
least the previous 2 wk. Infections such as
Mycoplasma, Chlamydia and respiratory syncy-
tial virus were ruled out in all asthma patients
by their serum antibody titers. The serum levels
of IL8; neutrophilic chemokine, eotaxin; eosin-
ophilic chemokine, monocyte chemoattractant
protein (MCP) 1; monocytic chemokine, vascu-
lar endothelial growth factor (VEGF) were
examined using enzyme linked immunosorbent
assays (ELISA) kit (Amersham Pharmacia
Biotech, Piscataway, NJ, USA). The detection
limits were 5.0, 5.0, 25.0 and 5.0 pg/ml,
respectively.
Low-dose EM (10 mg/kg/day divided twice)
was added on their current medications such as
inhaled steroid, leukotriene receptor antagonist
and theophylline for four severe-type patients;
two of four patients also suﬀered from allergic
pansinusitis. In addition, their clinical symptoms
and serum chemokines levels were compared
before and after 6 months of low-dose EM
therapy.
Moreover, three of four patients with severe-
type asthma had been administered theophylline
16 mg/kg/day divided twice for more than a year.
Before and 6 months after the co-administration
of low-dose EM and theophylline, theophylline
clearance, half-time and AUC (area under the
curve) were calculated using the THEOPRE-
DICT-III (Nikken Chemicals Co. Ltd, Tokyo,
Japan and Mitsubishi Pharma Co. Ltd, Tokyo,
Japan) based on 4–6 samples of the serum
theophylline concentrations such as trough lev-
els, and 4 and 6 h after administration. The daily
peak-trough ﬂuctuation rate of theophylline level
was calculated using the formula; (Cmax ) Cmin)/
Cmin.
A statistical examination was performed using
the Kruskal–Wallis test and the Wilcoxon signed
rank test.
Table 1. The Serum chemokine characterizations in patients with asthma
Severity (n) Control (10) Mild (28) Moderate (23)
Severe (4)
Before EM After EM
IL8 (pg/ml) 22.5 € 11.5 34.9 € 61.3 82.0 € 145.1 735.5 € 88.0 74.8 € 84.7
p = 0.036 p < 0.0005
Eotaxin (pg/ml) 36.2 € 8.3 67.1 € 38.2 51.0 € 16.5 49.7 € 23.5 45.0 € 28.8
p = 0.358 p = 0.778
MCP1 (pg/ml) 390 € 113 970 € 546 850 € 445 1869 € 382 1306 € 21
p = 0.078 p = 0.043
VEGF (pg/ml) 35.1 € 78.5 78.3 € 68.5 149.1 € 86.2 352.0 € 160.5 132.2 € 59.9
p = 0.005 p = 0.021
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As described in Table 1, the serum IL8 in-
creased according to asthma severity; healthy
controls, mild-type, moderate-type and severe-
type were 22.5 ± 11.5, 34.9 ± 61.3, 82.0 ±
145.1, 735.5 ± 88.0 pg/ml, respectively (p =
0.036). The serum VEGF also increased accord-
ing to severity; 35.1 ± 78.5, 78.3 ± 68.5,
149.1 ± 86.6, 352.0 ± 160.5 pg/ml, respectively
(p = 0.005).
After the administration of low-dose EM to
four severe-type patients, their clinical symptoms
improved (Table 2) and the levels of both IL8;
from 735.5 ± 88.0 to 74.8 ± 84.7 pg/ml
(p < 0.0005) and VEGF; from 352.0 ± 160.5
to 132.2 ± 59.9 pg/ml (p = 0.021) decreased
(Table 1). Both of the serum eotaxin levels and
serum MCP1 levels were not correlated with the
severity and EM administration.
After the co-administration of EM and the-
ophylline for three of four severe-type patients,
the theophylline clearance decreased from
0.093 ± 0.001 to 0.062 ± 0.013 l/kg/h, and the
half-time increased from 6.3 ± 1.0 to 9.9 ±
3.3 h and the AUC (area under the curve)
increased from 168.7 ± 74.4 to 261.7 ±
149.5 mg/CL · Wt. Such an altered theophylline
metabolism resulted in a decreased daily peak-
trough ﬂuctuation rate of the serum theophylline
concentration; (Cmax ) Cmin)/Cmin, from
1.3 ± 0.5 to 0.5 ± 0.3 (Table 2).
Discussion
Long-term low dose EM therapy has been
introduced for the treatment of diﬀuse panbron-
chiolitis and chronic pansinusitis (1). Low-dose
EM does not act as a bactericide but it inhibits
the IL8 production by the recruited neutrophils
(1). Although bronchial asthma is an essentially
caused by eosinophilic inﬂammation (6), an
association between asthma and neutrophilc
inﬂammation has been described in recent years.
Norzila MZ et al. (5), Marquet C et al. (7), and
Kikuchi I et al. (8) showed the recruitment of IL8
produced by neutrophils in patients with acute
asthma attack. Gounni AS et al.(9) described
that not only mast cells but also neutrophils of
patients with asthma express the high-aﬃnity
receptor for IgE, and the binding of IgE to the
receptor leads to IL8 production from the
neutrophils.
On the other hand, VEGF; one of the angio-
genic factors, is produced by neutrophil (10). It
has also been reported to be associated with
airway re-modeling; which is one of the exacer-
bation factors of asthma (11). The eﬀect of 14-
membered ring macrolide antibiotics on the
production of VEGF still remains unclear, how-
ever, the inhibition of VEGF derived from lung
cancer cells by roxithromycin has been reported
(12). EM might also inhibit VEGF in patients
with bronchial asthma.
Because of their immaturity regarding expira-
tory procedures, examinations using sputum tend
to be diﬃcult to perform in pediatric patients.
Therefore, serum chemokine examinations were
instead performed in this study.
Our results showed the severity of bronchial
asthma and the serum levels of IL8 and VEGF to
demonstrate a positive correlation; yet, there was
no signiﬁcant diﬀerence was observed in terms of
Table 2. Changes of clinical symptoms and theophylline metabolism in patients with severe-type asthma
Case Age (yr) Sex Before EM 6 months after EM
1 2 F Severe attack:1/1 month Severe attack:1/6 months
2 7 M Severe attack:1/2 months
%FEV1.0 120%
Moderate attack:1/6 months
%FEV1.0 145%
3 9 M Moderate attack:1/2 wk
%FEV1.0 55%
Moderate attack:1/2 months
%FEV1.0 77%
4 13 M Moderate attack:1/1 month
%FEV1.0 75%
Moderate attack:1/6 months
%FEV1.0 83%
TDM \ case 1 2 3 Mean
CL (l/kg/h) 0.094/0.077 0.093/0.055 0.092/0.054 0.093/0.062
t1/2 (h) 5.4/6.6 6.2/12.7 7.3/10.7 6.3/9.9
AUC (lg/h/ml) 99/120 247/418 160/247 169/262
Cmin (lg/ml) 3.0/8.2 7.8/15.1 3.5/9.2 4.8/10.8
Cmax (lg/ml) 6.5/14.7 14.9/18.0 10.3/14.2 10.6/15.6
Cmax ) Cmin/Cmin 1.2/0.8 0.9/0.2 1.9/0.5 1.3/0.5
(before/6 months after EM)
EM, erythromycin; %FEV1.0, % predict value of 1 second forced expiratory volume; CL, clearance; tl/2, half-time; AUC, area under the curve; C, concentration.
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491both serum eosinophilic chemokine eotaxin and
monocytic chemokine MCP1. Based on the
ﬁndings of eotaxin, eosinophilic inﬂammation
might already be inhibited by such long-term
medications as inhaled steroids, leukotriene
receptor antagonist, theophylline and others.
And thereafter, both IL8 and VEGF levels in
patients with severe-type were decreased after
6 months of the low-dose EM treatment regimen,
and followed by the improvement in clinical
symptoms of bronchial asthma.
These results suggest that the neutrophilic
inﬂammation thus plays a role in the severity of
standard therapies resistance bronchial asthma.
Because only two of four patients with severe
type asthma suﬀered from allergic pansinusitis,
the eﬀectiveness of low-dose EM therapy might
not only be due to the improvement of
nasal symptoms (13). Although infections of
Mycoplasma, Chlamydia and respiratory syncy-
tial virus, which cause acute neutrophilic inﬂam-
mation followed by transient wheezing (14), were
ruled out in these patients by their serum
antibody titers, some kind of chronic respiratory
infections might be persistent in intractable
patients with asthma.
Furthermore, an inhibition in the theophylline
metabolism, which was considered to be a side
eﬀect of EM, also demonstrated a beneﬁcial
eﬀect. In severe-type patients, it was found to be
diﬃcult to maintain the serum theophylline levels
within the therapeutic range; it therefore helped
to decrease the daily ﬂuctuations of the levels.
Since an increased dose of theophylline alone
would not help to induce an altered their daily
ﬂuctuation rates, this unexpected discovery
might thus be the second important mechanism
of low-dose EM therapy. Although theophylline
should be administered carefully because it
lowers the seizure threshold, especially in infan-
tile and/or febrile patients (15), it might be still
necessary for intractable asthma patients.
In this study, only four patients with severe-
type were examined because most pediatric
patients have become easier to control with
standard therapies such as inhaled steroids,
leukotriene receptor antagonist, theophylline
and others. For this limitation, a further large
scale double blind placebo control study should
be needed next. In patients with still intractable
asthma, low-dose EM therapy might be eﬀective
through the suppression of IL8 and VEGF and
maintenance of eﬀective theophylline levels.
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